- IntelGenx Corp. (IGX) has been issued U.S. Patent No. 11,471,406 by the United States Patent and Trademark Office (USPTO)
- The patent was issued with claims for modulating drug absorption in oral film dosage form designed for sublingual administration of various pharmaceuticals, including some cannabinoids
- This patent is expected to remain in force at least until 2038, not including any potential patent term extensions
- IntelGenx is a leading drug-delivery company focused on the development and manufacturing of pharmaceutical films
- IntelGenx Technologies Corp. was up 6.25 per cent, trading at $0.17 as at 10:01 AM ET
IntelGenx Corp. (IGX) has been issued U.S. Patent No. 11,471,406 by the United States Patent and Trademark Office (USPTO).
The patent was issued with claims for modulating drug absorption in oral film dosage form designed for sublingual administration of various pharmaceuticals, including some cannabinoids.
This patent, the latest in a series of recently granted to IntelGenx, is expected to remain in force until 2038, not including any potential patent term extensions.
The ‘406 patent issuance adds to the formidable intellectual property estate the company has been building for its VersaFilm oral film technology.
This patent will enable the development of a wide variety of protected products designed for improved drug delivery.
While this novel proprietary technology is covered by both U.S. Patent No. 10,828,254, previously granted to IntelGenx in November 2020, and the new ‘406 patent is suitable for cannabis-containing oral films, especially for THC oral film dosage forms, the ‘406 patent specifically covers an oral film dosage form designed for modulating absorption profile of sublingually administered actives.
“We are pleased with the continued development of the patent portfolio protecting our VersaFilm oral film technology,” stated Horst G. Zerbe, CEO of IntelGenx.
“This latest patent issuance demonstrates our strong commitment to protecting the innovation of our technology portfolio and the significant commercial opportunity that it represents for ourselves and our partners,” he added.
IntelGenx is a leading drug-delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx Technologies Corp. was up 6.25 per cent, trading at $0.17 as at 10:01 AM ET.
